Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialLancet 2022 Sep 09;[EPub Ahead of Print], E Livingstone, L Zimmer, JC Hassel, M Fluck, TK Eigentler, C Loquai, S Haferkamp, R Gutzmer, F Meier, P Mohr, A Hauschild, B Schilling, C Menzer, F Kiecker, E Dippel, A Roesch, M Ziemer, B Conrad, S Körner, C Windemuth-Kieselbach, L Schwarz, C Garbe, JC Becker, D Schadendorf
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.